Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Starpharma Holdings Limited ( (AU:SPL) ) has shared an announcement.
Starpharma Holdings Limited reported a 41% decline in revenue to $4.912 million for the year ending June 30, 2025, compared to the previous year. However, when excluding a one-time settlement from the prior year, adjusted revenue increased by 183%, driven by research revenue from Petalion Therapeutics and increased sales of Viraleze™ and VivaGel® BV. The company’s loss for the period rose by 22% to $9.99 million, though adjusted loss decreased by 32% due to reduced research and product development expenses. The financial results reflect ongoing investment in research and development, particularly in the DEP® drug delivery programs, which are crucial for the company’s strategic growth and industry positioning.
More about Starpharma Holdings Limited
Starpharma Holdings Limited operates in the pharmaceutical industry, focusing on the development and commercialization of innovative products based on its proprietary dendrimer technology. The company’s primary products include Viraleze™, a nasal spray, and VivaGel® BV, a treatment for bacterial vaginosis. Starpharma is also involved in drug delivery programs through its DEP® technology, targeting enhanced delivery of pharmaceuticals.
Average Trading Volume: 394,942
Technical Sentiment Signal: Hold
Current Market Cap: A$56.46M
Learn more about SPL stock on TipRanks’ Stock Analysis page.